Did you complete your Medicaid and CHIP renewal? Renew your benefits on COMPASS.
Head and Neck Cancer Clinical Trials
ECOG-ACRIN EA3161: A Phase III Randomized Study of Maintenance Nivolumab versus Observation in Patients with Locally Advanced, Intermediate Risk HPV Positive OPSCC.
The purpose of this study is to compare the usual treatment alone (radiation and chemotherapy) to adding maintenance nivolumab to the usual treatment for HPV positive oropharynx cancer.
ECOG/ACRIN-EA3132: Phase II Randomized Trial of Radiotherapy With or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) With TP53 Sequencing
This is a study to evaluate treatment after surgery for head and neck cancer. The purpose of this study is to compare two treatment approaches that are currently used after surgery for head and neck cancer.
Learn more about the ECOG/ACRIN- EA3132 trial or contact the Reading Hospital Protocol Office at 484-628-8193.
EA2174: A Phase II/III Study of Peri-operative Nivolumab and Ipilimumab in Patients with Locoregional Esophageal and Gastroesophageal Junction Adenocarcinoma
EA3132: Phase II Randomized Trial of Radiotherapy with or Without Cisplatin for Surgically Resected Squamous Cell Carcinoma of the Head and Neck (SCCHN) with TP53 Sequencing
NRG-HN005: A Randomized Phase II/III Trial of De-intensified Radiation Therapy for Patients with Early-Stage, p16-Positive, Non-Smoking Associated Oropharyngeal Cancer.
The purpose of this study is to compare the usual treatment of a standard-dose radiation given over six weeks with cisplatin chemotherapy to a reduced-dose radiation given over either six weeks with cisplatin or five weeks with the immunotherapy drug, nivolumab.
Learn more about the NRG-HN005 trial or call the Reading Hospital Protocol Office at 484-628-8193.
